Xvivo Perfusion Aktiebolag Stock: price and insider trades · Sweden

Every trade that managers of Xvivo Perfusion Aktiebolag disclose to Finansinspektionen is tracked on this page. The company sits in the Health Care sector and is based in Gothenburg, Sweden. It was founded in 1998. Over the twelve months to 18 October 2026, 4 filings were filed, from 3 insiders.

The flow runs one way only: 3 insiders bought (4 purchases totalling €103k) and nobody sold on the market. Unlike grants, an open-market purchase is paid for by the insider, at the market price. On the buying side, the filings list 1 board member, 1 finance chief and 1 chief executive among the declarants. At €43k, the purchase published on 22 July 2026 by Emil Billbäck is the largest of the period (0.0064% of market cap).

For context, the typical company on the same exchange (median of 890 companies) published 7 filings over the same period, against 4 filings here. Our records for Xvivo Perfusion Aktiebolag go back to 2025, with 10 purchases and no sales on the open market in total.

In the case of 1 purchase, another manager of the company was buying within the same 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The most recent open-market purchase was published on 22 July 2026, 87 days ago. Typically, a trade is published a median of 1 day after it takes place. The regulation allows three business days to notify a trade (MAR article 19).

In the same sector, recent insider purchases at Anixa Biosciences Inc and Vivos Inc also feature in our signals. Every figure here comes from the filings published by Finansinspektionen and describes the past, not future prices; it is not investment advice.